BEIJING (Reuters) – The Chinese bulk manufacturer of the common blood and heart drug valsartan said it was recalling the product from consumers in the United States and would halt supplies to the country, after an impurity linked to cancer had been detected.
Earlier this week, European regulators said the problem likely dates to changes in manufacturing processes at Zhejiang Huahai Pharmaceutical in 2012, suggesting that many patients could potentially have been exposed to cancer risk.
